Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 2, 2010, Pages 521-526

  Pugh, Thomas J ^a   Chen, Changhu ^a   Rabinovitch, Rachel ^a   Eckhardt, S Gail ^b   Rusthoven, Kyle E ^a   Swing, Robyn ^a   Raben, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Proteosome inhibitor; Radiation therapy; Solid tumor

Indexed keywords

BORTEZOMIB; CLINICAL TRIAL; DOSE ESCALATION; DOSE LEVELS; DOSE LIMITING TOXICITY; EXTERNAL BEAM RADIATION; EXTERNAL BEAM RADIATION THERAPY; HEAD AND NECK; HEMATOLOGIC TOXICITY; LYMPHOPENIA; MALIGNANT TUMORS; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NONHEMATOLOGIC TOXICITY; PHASE I; PROTEOSOME INHIBITOR; RADIATION THERAPY; SOLID MALIGNANCY; SOLID TUMOR; SOLID TUMORS;

RADIOTHERAPY; TOXICITY; TUMORS;

RADIATION;

BORTEZOMIB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANHEDONIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOATING; BLOOD TOXICITY; BLURRED VISION; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; CONSTIPATION; CREATININE BLOOD LEVEL; DEHYDRATION; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HERPES ZOSTER; HISTOLOGY; HOARSENESS; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INSOMNIA; KIDNEY CANCER; LEIOMYOSARCOMA; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROBLASTOMA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PYELONEPHRITIS; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIOGRAPHY; SIDE EFFECT; SOLID TUMOR; TASTE DISORDER; THERAPY DELAY; THROMBOCYTOPENIA; TUMOR BLEEDING; URINARY FREQUENCY; UROSEPSIS; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPENIA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PALLIATIVE THERAPY; PROCEDURES; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COLORADO; COMBINED MODALITY THERAPY; DIARRHEA; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOPENIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUTROPENIA; PALLIATIVE CARE; PYRAZINES;

EID: 79951716964     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1715     Document Type: Article

References (26)

1. D.P. Ryan, B.H. O'Neil, and J.G. Supko A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors Cancer 107 2006 2688 2697
2. C. Aghajanian, S. Soignet, and D.S. Dizon A phase I trial of the novel proteosome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 2002 2505 2511
3. R.Z. Orlowski, T.E. Stinchcombe, and B.S. Mitchell Phase I trial of the proteosome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 2002 4420-3327
4. S. Jagannath, B. Barlohie, and J. Berenson A phase 2 study of two doses of bortezomib in relapsed or refractory multiple myeloma Br J Haematol 127 2004 165 172
5. P.G. Richardson, B. Barlogie, and J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617
6. G.V. Kondagunta, B. Drucker, and L. Schwaryz Phase II trial of bortezomib for patients with advanced renal cell carcinoma J Clin Oncol 22 2004 3720 3725
7. C.N. Papandreou, D.D. Daliani, and D. Nix Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 11 2004 2108 2121
8. D.P. Ryan, L.J. Appleman, and T. Lynch Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors Cancer 107 10 2006 2482 2489
9. P.G. Richardson, P. Sonneveld, and M.W. Schuster Bortezomib or high dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498
10. S.M. Russo, J.E. Tepper, and A.S. Baldwin Enhancement of radiosensitivity by proteosome inhibition: implications for the role of NF-kappaB Int J Radiat Oncol Biol Phys 50 1 2001 May 1 183 193
11. W. Cao, K.T. Shiverick, and K. Namicki Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation World J Urol 26 5 2008; Oct 509 516
12. S. Kamer, Q. Ren, and A.P. Dicker Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341) Arch Gynecol Obstet 279 1 2009; Jan 41 46
13. C.N. Weber, G.J. Cerniglia, and A. Maity Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation Cancer Biol Ther 6 2 2007 156 159
14. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. May 22, 2003. http://ctep.cancer.gov.
15. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer for the European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, and National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
16. R.W. King, R.J. Deshaies, J.M. Peters, and M.W. Kirschner How proteolysis drives the cell cycle Science 274 1996 1652 1659
17. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
18. M.A. Read, A.S. Neish, and F.W. Luscinskas The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression Immunity 2 1995 493 506
19. V.J. Palombella, O.J. Rando, A.L. Goldberg, and T. Maniatis The ubiquin-proteosome pathway is required for processing the NF-Kβ1 precursor protein and the activation of NF-κB Cell 78 1994 773 785
20. B.R. Zetter Adhesion molecules in tumor metastasis Semin Cancer Biol 4 1993 219 229
21. A.A. Beg, and D. Baltimore An essential role for NF-κβ in preventing TNF-α induced cell death Science 274 1996 782 784
22. C. Van Waes, A.A. Chang, and P.F. Lebowitz Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and re-irradiation in patients with recurrent head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 63 5 2005 1400 1412
23. G.J. Kubicek, M. Werner-Wasik, and M. Machtay Phase I trial using proteasome inhibitor bortezomib and concurrent temolozomide and radiotherapy for central nervous system malignancies Int J Radiat Oncol Biol Phys 74 2 2009 433 439
24. J. Voortman, E.F. Smit, and R. Honeywell A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors Clin Cancer Res 13 12 2007 3642 3651
25. T. Cascone, M.P. Morelli, and F. Morgillo Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells J Cell Physiol 216 3 2008 698 707
26. C.M. Sloss, F. Wang, and R. Liu Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells Clin Cancer Res 14 16 2008 5116 5123